00:20 , Mar 7, 2018 |  BC Extra  |  Preclinical News

Calico team publishes on vanishing white matter disease

In a paper published in eLife, researchers from Calico Life Sciences LLC (South San Francisco, Calif.) and AbbVie Inc. (NYSE:ABBV) suggested that activating eukaryotic translation initiation factor 2B (EIF2B) could help treat vanishing white matter...
20:58 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other molecule...
13:10 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

BeyondSpring reports Phase II data for plinabulin to prevent chemotherapy-induced neutropenia

BeyondSpring Inc. (NASDAQ:BYSI) reported top-line data from 55 patients with advanced or metastatic non-small cell lung cancer (NSCLC) who failed platinum-based therapy in the Phase II portion of the Phase II/III Study 105 (Protective-1) to...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other molecule...
01:15 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Mouse studies suggest inhibiting ARHGEF1 could help treat atherosclerosis. In an LDLR-deficient mouse model of atherosclerosis, ARHGEF1 knockout decreased the formation of atherosclerotic lesions compared with normal expression. In two bone marrow-ablated, LDLR-deficient mouse...
18:28 , Mar 21, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma Patient sample and cell culture studies suggest inhibiting VAV2 could help treat adrenocortical carcinoma (ACC). In patients, high tumor expression of VAV2 was associated with poor overall survival and disease-free survival. In a chicken...
19:34 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Patient sample, cell culture and mouse studies suggest inhibiting MYD88 could help treat atopic and allergic dermatitis. In patient skin lesion samples, levels of MYD88 were higher and levels of its upstream signaling protein...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 (PREX1) levels predict response to phosphoinositide 3-kinase (PI3K) inhibition In vitro studies suggest PREX1 expression...
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of sympathetic nervous system activation in metabolic syndrome A new mouse model could help guide development of...
07:00 , Jun 20, 2013 |  BC Innovations  |  Cover Story

Interfacing with Ras

A German team has identified a compound that disrupts a protein-protein interaction that localizes K-Ras to the cell membrane, thus inhibiting tumor growth.1 The interface provides a new small molecule binding site for the handful...